Post hoc analysis of ARCHES and PROSPER (N=2551): radiographic progression without PSA rise was more frequent with enzalutamide plus ADT than control (25.3% vs 7.4% in mHSPC; 21.9% vs 3.6% in nmCRPC), and rPD with or without PSA rise carried worse OS.
Secondary analysisn = 2,551
Armstrong et al. Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide